Security key
097702104
Bolt Biotherapeutics, Inc. - Common Stock, par value $0.00001 per share (BOLT)
CUSIP: 097702104
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Total 13F shares
- 18,782,186
- Total 13F value
- $12,170,936
- Share change
- -3,846,084
- SEC-reported price per share
- $0.65
- Number of holders
- 31
- Value change
- -$2,809,769
- Number of buys
- 9
- Number of sells
- 12
- Shares outstanding
- 38,512,859
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
31
Top holders
10
BOLT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Bolt Biotherapeutics, Inc. SEC filings
Bolt Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 097702104
Recent filing periods:
Ownership snapshot
Top reported holders of BOLT - Bolt Biotherapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TANG CAPITAL MANAGEMENT LLC
Disclosed value leader
TANG CAPITAL MANAGEMENT LLC
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
Lead comparable stake: 9.9%
Showing 1-6 of 15 holder rows.
Quick read
TANG CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TANG CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
TANG CAPITAL MANAGEMENT LLC
9.9%
Vivo Capital, LLC
9.1%
Sofinnova Investments, Inc.
7.2%
CITADEL ADVISORS LLC
6.1%
Pivotal bioVenture Partners Inves...
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC |
13F
Company
|
9.9%
|
$2,859,580
3,812,773 shares
|
— | 30 Jun 2024 |
| Vivo Capital, LLC |
13F
Company
|
9.1%
|
$2,640,968
3,521,291 shares
|
— | 30 Jun 2024 |
| Sofinnova Investments, Inc. |
13F
Company
|
7.2%
|
$2,065,828
2,754,437 shares
|
— | 30 Jun 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
6.1%
|
$1,775,634
2,367,511 shares
|
— | 30 Jun 2024 |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
Company
|
4.9%
|
$1,418,600
1,891,467 shares
|
— | 30 Jun 2024 |
| Newtyn Management, LLC |
13F
Company
|
3.5%
|
$1,022,425
1,363,234 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
18,782,186
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q3 2025 Across Filers
Q3 2025 holders
1
Q3 2024 holders
31
Holder diff
30
| Investor | Q3 2025 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q3 2025 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend